Singular GenomicsOMIC
About: Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Employees: 127
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
207% more capital invested
Capital invested by funds: $6M [Q2] → $18.4M (+$12.4M) [Q3]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
18.25% more ownership
Funds ownership: 28.75% [Q2] → 47.0% (+18.25%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
8% less funds holding
Funds holding: 24 [Q2] → 22 (-2) [Q3]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for OMIC.
